Literature DB >> 30358878

The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy.

Yishay Wasserstrum1, Roberto Barriales-Villa2,3, Xusto Fernández-Fernández3,4, Yehuda Adler1, Dor Lotan1, Yael Peled1, Robert Klempfner1, Rafael Kuperstein1, Nir Shlomo1, Avi Sabbag1, Dov Freimark1, Lorenzo Monserrat3,4, Michael Arad1.   

Abstract

AIMS: Diabetes mellitus (DM) aggravates the clinical features of ischaemic and hypertensive heart diseases and worsens the prognosis of heart failure patients. Hypertrophic cardiomyopathy (HCM) and diabetes coexist fairly frequently in elderly patients but the impact of DM on the clinical phenotype of HCM is yet unknown. We sought to describe if predominant features of heart failure in DM patients exist independently in HCM. METHODS AND
RESULTS: We reviewed clinical characteristics of 937 patients, age ≥40, diagnosed with HCM, from two tertiary medical centres in Spain and Israel. A propensity score matched cohort of 294 patients was also analysed. Our cohort comprised 102 HCM patients with diabetes (8.7%). Patients with DM were older at diagnosis {median 56 [interquartile range (IQR) 47-67] vs. 53 (IQR 43-63), P = 0.02} and had a higher prevalence of comorbidities. Hypertrophic cardiomyopathy patients with DM had a higher prevalence of diastolic dysfunction, pulmonary hypertension, significant mitral regurgitation, and pacemaker implantation. Hypertrophic cardiomyopathy patients with DM had a higher New York Heart Association (NYHA) class (P < 0.001) and lower exercise capacity [7.0 METS (IQR 5.0-10.0) vs. 9.0 METS (IQR 6.6-11.0), P = 0.002]. These findings were independent of age, gender, country of origin, hypertension, and coronary artery disease. Patients with diabetes had a significantly higher 15-year mortality (22% vs. 15%, P = 0.03), with no differences in sudden cardiac death, appropriate implanted cardioverter-defibrillator therapy, or heart transplantation.
CONCLUSION: Hypertrophic cardiomyopathy patients with diabetes are older and have a higher cardiovascular risk profile. They have a lower functional capacity and more heart failure symptoms due to diastolic dysfunction. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Diabetes mellitus ; Diastolic dysfunction; Functional capacity ; Heart failure ; Hypertrophic cardiomyopathy

Mesh:

Year:  2019        PMID: 30358878     DOI: 10.1093/eurheartj/ehy625

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

Review 1.  Targeted Medical Therapies for Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Maria Grazia De Gregorio; Mattia Zampieri; Elisa Fedele; Alessia Tomberli; Chiara Chiriatti; Alberto Marchi; Iacopo Olivotto
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

2.  Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.

Authors:  James S Ware; Connie R Bezzina; Martin Farrall; Hugh Watkins; Andrew R Harper; Anuj Goel; Christopher Grace; Kate L Thomson; Steffen E Petersen; Xiao Xu; Adam Waring; Elizabeth Ormondroyd; Christopher M Kramer; Carolyn Y Ho; Stefan Neubauer; Rafik Tadros
Journal:  Nat Genet       Date:  2021-01-25       Impact factor: 38.330

3.  Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.

Authors:  Yishay Wasserstrum; José M Larrañaga-Moreira; Cristina Martinez-Veira; Edward Itelman; Dor Lotan; Avi Sabbag; Rafael Kuperstein; Yael Peled; Dov Freimark; Roberto Barriales-Villa; Michael Arad
Journal:  ESC Heart Fail       Date:  2022-04-30

4.  Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy.

Authors:  Shengwei Wang; Hao Cui; Keshan Ji; Changpeng Song; Changwei Ren; Hongchang Guo; Changsheng Zhu; Shuiyun Wang; Yongqiang Lai
Journal:  Cardiovasc Diabetol       Date:  2020-05-13       Impact factor: 9.951

5.  Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin.

Authors:  Perundurai S Dhandapany; Soojeong Kang; Deepak K Kashyap; Raksha Rajagopal; Nagalingam R Sundaresan; Rajvir Singh; Kumarasamy Thangaraj; Shilpa Jayaprakash; Cholenahally N Manjunath; Jayaprakash Shenthar; Djamel Lebeche
Journal:  Sci Adv       Date:  2021-01-06       Impact factor: 14.957

6.  Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy.

Authors:  Jing Yu; Huanhuan Zhao; Xin Qi; Liping Wei; Zihao Li; Chunpeng Li; Xiaoying Zhang; Hao Wu
Journal:  Front Pharmacol       Date:  2021-09-23       Impact factor: 5.810

Review 7.  Major Clinical Issues in Hypertrophic Cardiomyopathy.

Authors:  Hyung-Kwan Kim; Sang Chol Lee; Hyun-Jung Lee; Jihoon Kim; Sung-A Chang; Yong-Jin Kim
Journal:  Korean Circ J       Date:  2022-08       Impact factor: 3.101

8.  A case report of refractory angina in a patient with diabetes and apical hypertrophic cardiomyopathy.

Authors:  Nicholas Jex; Amrit Chowdhary; Sharmaine Thirunavukarasu; Eylem Levelt
Journal:  Eur Heart J Case Rep       Date:  2022-08-16

Review 9.  Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier.

Authors:  Edgar E Nollet; B Daan Westenbrink; Rudolf A de Boer; Diederik W D Kuster; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-11-11       Impact factor: 6.106

10.  Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction.

Authors:  Yumin Li; Jia Liu; Yukun Cao; Yue Cui; Heshui Shi; Xiaoyu Han; Guozhu Shao; Xiaoyue Zhou; Jin Gu; Tong Liu
Journal:  Sci Rep       Date:  2021-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.